POONGJEON PHARMACY CO.,LTD. (298060) Fair Value & Analysis
Healthcare · KR · Market cap 25.2B KRW
Fair value as of: Jun 24, 2026
Analysis
POONGJEON PHARMACY CO.,LTD. (298060) currently trades at 2,610 KRW, while our model-based Fair Value estimate is 939.74 KRW — implying the stock looks roughly 64.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
POONGJEON PHARMACY CO.,LTD. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was formerly known as SCM Lifescience Co., Ltd. and change its name to POONGJEON PHARMACY CO.,LTD. in April 2026. The company was incorporated in 2014 and is headquartered in Incheon, South Korea.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is POONGJEON PHARMACY CO.,LTD. (298060) undervalued?
What is the fair value of 298060?
What is the quality score of 298060?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.